Clinical Trial: Deucravacitinib in PG

Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Study Type: INTERVENTIONAL

Official Title: Novel Treatment of Pyoderma Gangrenosum With Deucravacitinib

Brief Summary: The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).

Detailed Summary:
Sponsor: Dartmouth-Hitchcock Medical Center

Current Primary Outcome: PGA will be used for overall assessment of efficacy.

Original Primary Outcome: PGA will be used for overall assessment of efficacy.

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Dartmouth-Hitchcock Medical Center

Dates:
Date Received: March 20, 2023
Date Started: November 01, 2023
Date Completion: November 01, 2023
Last Updated: July 31, 2023
Last Verified: July 01, 2023